Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
TLC completes patient enrollment in TLC590 Phase II clinical trial » 05:29
02/12/20
02/12
05:29
02/12/20
05:29
TLC

Taiwan Liposome

$5.10 /

+ (+0.00%)

TLC announced the…

TLC announced the earlier-than-scheduled completion of patient enrollment in Part 2 of the TLC590 Phase II clinical trial, which is taking place across four sites in the United States. The randomized, double-blind, comparator- and placebo-controlled study will evaluate the analgesic efficacy and safety of TLC590 for postsurgical pain management in patients following bunionectomy. Topline data is expected to be reported in mid-2020. TLC590 is a non-opioid, proprietary BioSeizer sustained release formulation of ropivacaine intended to manage postsurgical pain for three days or more with a single dose, potentially reducing the need for opioids following surgery. In Part 1 of the two-part Phase II clinical trial following bunionectomy, the safety, dose linearity and relative bioavailability of TLC590 were established based on 50 patients.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Conference/Events
Taiwan Liposome management to meet with Oppenheimer » 04:55
01/21/20
01/21
04:55
01/21/20
04:55
TLC

Taiwan Liposome

$5.30 /

-0.16 (-2.93%)

Meeting to be held in New…

Meeting to be held in New York on January 21 hosted by Oppenheimer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Taiwan Liposome management to meet with Oppenheimer » 07:57
01/16/20
01/16
07:57
01/16/20
07:57
TLC

Taiwan Liposome

$5.43 /

+0.03 (+0.56%)

Meeting to be held in New…

Meeting to be held in New York on January 21 hosted by Oppenheimer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Taiwan Liposome doses first patient in Part 2 of TLC590 Phase II trial » 05:25
01/08/20
01/08
05:25
01/08/20
05:25
TLC

Taiwan Liposome

$5.60 /

+ (+0.00%)

TLC announced that the…

TLC announced that the first batch of patients has been dosed in Part 2 of the Phase II clinical trial for TLC590 in patients following bunionectomy surgery. TLC590 is a non-opioid, proprietary BioSeizer sustained release formulation of ropivacaine intended to manage postsurgical pain for three days or more with a single dose, potentially reducing the need for opioids following surgery.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Taiwan Liposome assumed with an Overweight at Cantor Fitzgerald » 07:11
12/23/19
12/23
07:11
12/23/19
07:11
TLC

Taiwan Liposome

$5.70 /

+0.4 (+7.55%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska assumed coverage of Taiwan Liposome with an Overweight rating and $11 price target. The company uses lipid-assembled drug technologies to deliver approved active pharmaceutical ingredients, Kluska tells investors in a research note. The analyst believes these platforms allow for drug delivery in a controlled, carefully designed manner that could lead to faster onset as well as increased duration of treatment effect.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Taiwan Liposome Company Ltd (ADS) trading resumes  12:39
12/16/19
12/16
12:39
12/16/19
12:39
TLC

Taiwan Liposome

$5.40 /

+0.1 (+1.89%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Taiwan Liposome Company Ltd (ADS) trading halted, volatility trading pause  12:29
12/16/19
12/16
12:29
12/16/19
12:29
TLC

Taiwan Liposome

$5.30 /

+ (+0.00%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Hot Stocks
TLC enrolls first patient in EXCELLENCE Phase III pivotal clinical trial » 05:25
11/27/19
11/27
05:25
11/27/19
05:25
TLC

Taiwan Liposome

$4.90 /

+ (+0.00%)

TLC announced that the…

TLC announced that the first patient has been enrolled in EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis, or OA, knee pain. TLC599 is a non-opioid, proprietary BioSeizer sustained release formulation of dexamethasone sodium phosphate intended to manage OA pain for up to six months.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Taiwan Liposome reports Q3 EPS (9c), consensus (21c) » 06:11
10/22/19
10/22
06:11
10/22/19
06:11
TLC

Taiwan Liposome

$5.00 /

+ (+0.00%)

Reports Q3 revenue…

Reports Q3 revenue $600,000, consensus $650,000. The Company's cash and cash equivalents and time deposits with maturity over three months were $32.5M as of September 30 compared to $36.4M as of December 31, 2018.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Janney Montgomery Scott to hold a conference » 04:55
09/10/19
09/10
04:55
09/10/19
04:55
AGRX

Agile Therapeutics

$1.35 /

+ (+0.00%)

, AGTC

Applied Genetic

$3.80 /

+0.04 (+1.06%)

, ALDX

Aldeyra

$4.91 /

-0.035 (-0.71%)

, ANIX

Anixa Biosciences

$4.12 /

+0.09 (+2.23%)

, AVRO

Avrobio

$20.87 /

-0.11 (-0.52%)

, BDSI

BioDelivery Sciences

$4.43 /

+0.03 (+0.68%)

, BLFS

BioLife Solutions

$19.55 /

-0.03 (-0.15%)

, CEMI

Chembio Diagnostics

$5.91 /

-0.05 (-0.84%)

, CNCE

Concert Pharmaceuticals

$10.67 /

-0.54 (-4.82%)

, COLL

Collegium Pharmaceutical

$11.24 /

+0.415 (+3.83%)

, DYAI

Dyadic International

$5.45 /

-0.43 (-7.31%)

, EBS

Emergent BioSolutions

$56.68 /

+0.665 (+1.19%)

, FLDM

Fluidigm

$5.45 /

-0.1 (-1.80%)

, FOLD

Amicus

$9.51 /

+0.28 (+3.03%)

, NEO

NeoGenomics

$23.30 /

-1.36 (-5.52%)

, SBBP

Strongbridge Biopharma

$2.77 /

+0.095 (+3.55%)

, SMMT

Summit Therapeutics

$1.35 /

+ (+0.00%)

, SPRO

Spero Therapeutics

$11.07 /

+1.15 (+11.59%)

, TLC

Taiwan Liposome

$5.06 /

-0.09 (-1.75%)

, VCYT

Veracyte

$24.92 /

-0.73 (-2.85%)

Healthcare Conference…

Healthcare Conference 2019 will be held in New York on September 9-10.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.